Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 112 posts
August 25, 2020 | Blog
COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.
August 25, 2020 | Infographics
CBPartners lists the top 10 long-term trends and implications of COVID-19 on the biopharma industry as biopharma leaders prepare for a post-COVID-19 world.
August 5, 2020 | Blog
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.
August 5, 2020 | Infographics
July 24, 2020 | News
In solidarity with the BLM movement, and as a firm committed to inclusivity, diversity, and a safe environment for all, CBPartners donated $25,000 cumulatively to Campaign Zero and Know Your Rights on behalf of everyone at the firm.